Navigation Links
Perrigo Files Registration Statement On Form S-4 In Connection With Proposed Acquisition Of Elan
Date:8/28/2013

therwise.

Elan's principal source of revenue may remain a royalty on sales of Tysabri®, the potential of Tysabri®, which may be severely constrained by increases in the incidence of serious adverse events (including death) associated with Tysabri® (in particular, by increases in the incidence rate for cases of PML), or by competition from existing or new therapies (in particular, oral therapies), and the potential for the successful development and commercialisation of products, whether internally or by acquisition, especially given the separation of the Prothena business which left Elan with no material pre-clinical research programs or capabilities; Elan's ability to maintain sufficient cash, liquid resources, and investments and other assets capable of being monetised to meet its liquidity requirements; the success of Elan's development activities, and R&D activities in which Elan retains an interest, including, in particular, the impact of the announced discontinuation of the development of bapineuzumab intravenous in mild to moderate Alzheimer's disease; failure to comply with anti-kickback, bribery and false claims laws in the United States, Europe and elsewhere; difficulties or delays in manufacturing and supply of Tysabri®; trade buying patterns; the impact of potential biosimilar competition, the trend towards managed care and health care cost containment, including Medicare and Medicaid; legislation and other developments affecting pharmaceutical pricing and reimbursement (including, in particular, the dispute in Italy with respect to Tysabri® sales), both domestically and internationally; failure to comply with Elan's payment obligations under Medicaid and other governmental programs; exposure to product liability (including, in particular, with respect to Tysabri®) and oth
'/>"/>

SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution
2. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
3. Perrigo Company to Present at the UBS Global Life Sciences Conference
4. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
5. Coalition to Save Pure Files Proxy Documents With SEC, Urges Pures Board to Set an Annual Meeting Date
6. Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case
7. Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration
8. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
9. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
10. Ronald L. Chez Files Amended 13D and Letter to the Board
11. China Cord Blood Corporation Files its Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... June 22, 2014 Even within a phylum so full ... distinguished among other arthropods for its cruelty -- at least ... America, the fly is a most predatory sort of parasite. ... deposits a smear of larvae, and leaves its wicked brood ... , None of this would be possible without the ...
(Date:7/22/2014)... water with ultrasound and they,ll spin around their long ... knows exactly. But researchers at the National Institute of ... fast. At up to 150,000 revolutions per minute, these ... submerged in liquid ever reported. , The discovery of ... they could be used not only for moving around ...
(Date:7/22/2014)... , July 22, 2014   BioTE ... therapy using natural, bio-identical hormone pellets, today announced ... MD to the company.   Dr. Rouzier is joining ... physician.      Dr. Rouzier was residency ... UCLA and is a board certified emergency physician ...
(Date:7/22/2014)... Alachua, Fla. (PRWEB) July 22, 2014 ... cyclodextrins for the pharmaceutical, medical device, cosmetics, and other ... Private Placement with a group of qualified private investors ... Pharmacia. , The transaction involved the ... Holdings issued 1,725,000 shares of Common Stock at a ...
Breaking Biology Technology:Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3
... (Nasdaq: CHDX ) a leading independent American provider ... of China,announced that it intends to release its financial ... Thursday, June 12, 2008., Chindex,s management will also ... 9:00 a.m. Eastern Time to discuss its financial results., ...
... Quarter ... Salesforce ... Insulet Corporation,(Nasdaq: PODD ), a leader in wearable insulin ... for,the first quarter ended March 31, 2008., First quarter 2008 ...
... Inc.,(NYSE: HSP ), a global specialty pharmaceutical ... Bowles, CFA, has been elected to,the company,s board ... expertise from leadership positions held at major,multinational consumer ... of Bowles expands Hospira,s board to nine directors, ...
Cached Biology Technology:Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 3Insulet Reports First Quarter 2008 Results 2Insulet Reports First Quarter 2008 Results 3Insulet Reports First Quarter 2008 Results 4Insulet Reports First Quarter 2008 Results 5Insulet Reports First Quarter 2008 Results 6Insulet Reports First Quarter 2008 Results 7Hospira Expands Board of Directors 2
(Date:7/22/2014)... you,re allergic to dust mites (and chances are you ... at the University of Iowa have developed a vaccine ... body,s immune response. In animal tests, the nano-sized vaccine ... exposure to the allergens, according to the paper, published ... Scientists) Journal . One big reason why it ...
(Date:7/22/2014)... be on the horizon. Bacteria that produce a ... insulin resistance and other adverse effects of a ... discovered., "Of course it,s hard to speculate from ... Ph.D., assistant professor of Pharmacology. "But essentially we,ve ... in mice, even though they,re eating a high-fat ...
(Date:7/22/2014)... The challenges faced by researchers in modifying properties of ... a simple technique, thanks to recent innovative studies conducted ... , Through the use of a simple, efficient and ... NUS research teams, led by Professor Sow Chorng Haur ... of Science, demonstrated that the properties of two different ...
Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Vanderbilt study shows therapeutic bacteria prevent obesity in mice 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3
... has shown that enhancing the production of a protein ... neuron death associated with Alzheimer,s, at the expense of ... amyloid-beta protein plaques within the brain is a major ... contribute to disease progression. Normally, special enzymes chew up ...
... peas to show that one copy of a gene (allele) is ... the progeny, the inherited genes are expressed at the right time ... that although gene products could be modified during the life of ... Now it appears that one copy of some genes ...
... ARLINGTON, Va., June 10 Stanley, Inc. (NYSE:,SXE), ... services,to the U.S. federal government, announced today that ... Oberon Associates, Inc. (Oberon), an,engineering, intelligence operations and ... approximately $170 million in cash,subject to certain working ...
Cached Biology News:Genome communication 2Genome communication 3Genome communication 4Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4
... an automated multiplexing platform that uses advanced ... sequence detection and pharmacogenetics applications. Multiple samples ... an open and flexible electronic microarray, the ... all tests sites have been utilized. This ...
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
... D kit is an enzymeimmunoassay intended ... D (25-OH D) and other hydroxylated ... Our patented DIRECT assay technology eliminates ... centrifugation and therefore facilitates automation on ...
Biology Products: